CONBA(SH:600572)2019-04-24 16:00Financial Performance - Operating revenue for the first quarter was ¥1,688,358,242.03, a decrease of 5.27% year-on-year, primarily due to a high revenue base from cold medicine products in the same period last year[14][15] - Net profit attributable to shareholders was ¥176,198,966.73, down 34.22% compared to the same period last year[14] - The weighted average return on equity decreased by 1.40 percentage points to 3.17%[14] - The company reported a net profit margin decline due to reduced revenue, impacting overall profitability[50] - The company reported a total of ¥1.09 billion in payable bonds, indicating a significant portion of long-term financing[71] Cash Flow - The net cash flow from operating activities increased by 49.33% year-on-year, amounting to ¥199,422,600.68[14] - Cash inflow from operating activities totaled CNY 1,956,472,434.84, an increase from CNY 1,736,204,500.08 in the previous year, representing a growth of approximately 12.67%[61] - Net cash flow from investing activities improved significantly to RMB 30,460,222.15, a 128.46% increase from a negative RMB 107,023,233.99, due to the completion of securities disposals[27] - Cash inflow from financing activities reached CNY 435,333,000.00, compared to CNY 136,620,000.00 in the prior year, marking an increase of approximately 218.5%[63] Assets and Liabilities - Total assets at the end of the reporting period reached ¥10,921,055,393.91, an increase of 1.94% compared to the end of the previous year[14] - Total liabilities increased to CNY 5,155,316,836.35 from CNY 4,920,817,677.93, reflecting a growth of 4.78%[46] - The company reported short-term borrowings of 1,280,900,000.00, indicating a significant liability position[68] - The company has a total of approximately $368.14 million in other payables, including interest payable of about $20.19 million[77] Shareholder Information - The number of shareholders at the end of the reporting period was 115,205, with the largest shareholder, 康恩贝集团有限公司, holding 707,248,411 shares, representing 26.52%[21] - The top ten shareholders collectively hold a significant portion of shares, with the top two shareholders alone accounting for 35.32% of total shares[21] - The company has no preferred shareholders as of the reporting period[24] Research and Development - The company is focusing on expanding its R&D capabilities, as indicated by the increase in prepayments for R&D expenses[25] - Research and development expenses increased to CNY 8,067,707.36 in Q1 2019 from CNY 8,799,749.89 in Q1 2018[54] Investment Activities - The company recognized an investment loss of ¥15,784,300 from its stake in Jiahe Biological Pharmaceuticals during the reporting period[17] - The company reported an investment loss of CNY -24,327,428.16 in Q1 2019, compared to a profit of CNY 74,565,811.45 in Q1 2018[58] Other Financial Metrics - Financial expenses increased by ¥20,826,800 due to a rise in bank borrowings compared to the same period last year[17] - Other income rose to RMB 33,035,891.11, reflecting a 116.81% increase from RMB 15,237,097.38, attributed to increased government subsidies[27] - The company reported a significant increase in financial expenses, totaling RMB 30,372,666.80, up 218.18% from RMB 9,545,898.99 due to increased bank borrowings[27] Company Developments - The company is actively working on the processing of industrial hemp, having received approval for its project and is in the process of upgrading production lines[33] - The company plans to acquire 100% equity of a subsidiary for RMB 30 million and will inject an additional RMB 60 million into the subsidiary[34] - The company established Yunnan Kangma Biotechnology Co., Ltd. with a registered capital of RMB 100 million, holding 30% equity[35]